scispace - formally typeset
C

Chien-Feng Li

Researcher at National Health Research Institutes

Publications -  218
Citations -  4509

Chien-Feng Li is an academic researcher from National Health Research Institutes. The author has contributed to research in topics: Cancer & Nasopharyngeal carcinoma. The author has an hindex of 34, co-authored 191 publications receiving 3636 citations. Previous affiliations of Chien-Feng Li include Chung Hwa University of Medical Technology & Kaohsiung Medical University.

Papers
More filters
Journal ArticleDOI

Periostin overexpression is associated with worse prognosis in nasopharyngeal carcinoma from endemic area: a cohort study.

TL;DR: High POSTN expression is associated with tumor aggressiveness and worse clinical outcomes in NPC, indicating that it may be a potential prognostic biomarker and a therapeutic target.
Journal ArticleDOI

Characterization and Prognostic Significance of Methylthioadenosine Phosphorylase Deficiency in Nasopharyngeal Carcinoma.

TL;DR: MTAP deficiency was correlated with an aggressive phenotype and independently predictive of worse DSS and DMFS, suggesting its role in disease progression and as an independent prognostic biomarker of NPC, which potentially offers new strategy of targeted treatment for patients lacking MTAP expression.
Journal ArticleDOI

Overexpression of Pyruvate Dehydrogenase Kinase-3 Predicts Poor Prognosis in Urothelial Carcinoma.

TL;DR: In this paper, the role and prognostic value of PDK3 expression in patients with upper urinary tract urothelial carcinoma (UTUC) and urinary bladder urotheal cancer (UBUC) were investigated by Pearson's chi-square test, Kaplan-meier analysis, and multivariate Cox proportional hazards model.
Journal ArticleDOI

Synchronous presentation of uterine leiomyosarcoma and retroperitoneal liposarcoma: analysis by comparative genomic hybridization and review of the literature.

TL;DR: Both metastasis and multiple primary tumors should always be taken into consideration in differential diagnosis while encountering synchronous sarcomas, as well as unrelated genomic alterations of these 2 tumors.